Dr. Merali received his BS, MS, and PhD degrees in Biochemistry from The City University of New York. While completing his doctoral program, Dr. Merali joined New York University (1992-2005) to work on drug development on opportunistic fungal pathogens in AIDS (Pneumocystis). He also developed state of the art technology in Proteomics and Metabolomics. He joined Temple University School of Medicine (2005-2013) as Associate Professor of Biochemistry, The Fels Institute of Cancer Research and Molecular Biology, and Director of the Proteomics Core Facility. He became a member of Fox Chase Cancer Institute in 2012. Dr Merali joined the School of Pharmacy in 2013. Dr. Merali is an expert in the study of Pneumocystis infection and the use of S-adenosylmethionine as a marker for monitoring infection. He has been a key liaison for translational medicine research with regards to teaching and supervising infectious disease fellow, surgical residents and graduate students. He has vast expertise in Proteomics and Metabolomics applied to biomarker discovery, disease pathogenesis and identification of novel drug targets in COPD, obesity/diabetes, cancer, Pneumocystis, and neuroAIDS. He is the principal author of 7 patents. He is also the principal author or co-author of 68 publications. He is a member of several NIH study sections and has been invited to many lectureships.

Dr. Merali research interestsinclude Proteomics and Metabolomics applied to biomarker discovery, disease pathogenesis and identification of novel drug targets in COPD, obesity/diabetes, cancer, Pneumocystis, and neuroAIDS.